Collegium Pharmaceutical downgraded by H.C. Wainwright
$COLL
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright downgraded Collegium Pharmaceutical from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | $46.00 | Hold → Buy | Needham |
| 7/30/2024 | $47.00 | Neutral → Buy | H.C. Wainwright |
| 6/7/2024 | $41.00 → $44.00 | Hold → Buy | Jefferies |
| 5/10/2024 | Buy → Hold | Needham | |
| 5/10/2024 | $39.00 | Overweight → Neutral | Piper Sandler |
| 1/4/2024 | $30.00 → $37.00 | Buy → Hold | Jefferies |
| 8/25/2023 | $35.00 → $36.00 | Buy | Needham |
| 5/2/2023 | $30.00 | Buy | Jefferies |
STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in the following investor conferences: Mizuho Neuro & Ophthalmology Summit 2025Panel Presentation: Wednesday, May 21, 2025, at 11:25 a.m. ET Jefferies Global Healthcare ConferencePresentation: Thursday, June 5, 2025, at 1:25 p.m. ET The presentation at Jefferies Global Healthcare Conference will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Collegium Pharm
STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $65 million remaining under the program. "Collegium is off to a strong start in 2025 with first quarter revenues g
– Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Confer
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie
– Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives Appointed to Leadership Team; David Dieter, as Executive Vice President, General Counsel Jane Gonnerman as Executive Vice President, Strategy and Corporate Development and Dean J. Patras, as Chief People Officer – STOUGHTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company, today announced updates to its Board of Directors and appointments of three new executive leaders as the C
STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. "Collegium is pleased to welcome Nancy to our Board of Directors," said Mike Heffernan, Founder and Chairman of the Board of Collegium. "Nancy's expertise in driving commercial growth and strategic acquisitions will be of great value to Collegium as we continue to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions." "This is a pivotal and exciting time for Collegium as it embarks on a new stage of growth
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
SCHEDULE 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
SC 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
Needham upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $46.00
H.C. Wainwright upgraded Collegium Pharmaceutical from Neutral to Buy and set a new price target of $47.00
Jefferies upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $44.00 from $41.00 previously
– Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Confer
STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q1 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the Compa
– Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $107.7 Million and $401.2 Million – – Ended 2024 with Cash, Cash Equivalents and Marketable Securities of $162.8 Million; Repurchased $60.0 Million in Shares in 2024 – – Reaffirmed Full-Year 2025 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON,